iiinova — where your digital self keeps evolving

Reposted by Cristina Popa

Nephrology Journal Club @nephjc.bsky.social · 30/09/2026

11/10 ➡️Up next on 10/13: Survival benefit of deceased donor kidney transplantation versus continued dialysis: international target trial emulation | The BMJ www.bmj.com/content/394/... Join us www.nephjc.com/

nephjc.com

NephJC

031

Reposted by Cristina Popa

Nephrology Journal Club @nephjc.bsky.social · 30/09/2026

1/10 #NephJC #TenPosts #NephSly 🫘💊 START your steroids! A question we ask constantly but adult RCT data rarely answers after remission in steroid-sensitive MCD/FSGS, how long should the prednisolone taper actually be? 🧵 www.sciencedirect.com/science/arti...

sciencedirect.com

155

Reposted by Cristina Popa

Nephrology Journal Club @nephjc.bsky.social · 03/10/2026

Can tolvaptan keep up with 3% saline? This within-subject study in healthy volunteers delivered a surprising answer - and a few eyebrow-raising physiology twist. Dive in #NephJC ✍️ by @drsaivani.bsky.social www.nephjc.com/news/tolvapt...

nephjc.com

Raising sodium: can tolvaptan rival 3% hypertonic saline? — NephJC

Testing Tolvaptan versus 3% saline and the rate of rise of serum sodium in healthy volunteers.

176

Cristina Popa @nephroseeker.medsky.social · 03/10/2026

8/ Future trials must fix the usual pitfalls: 🚩 Phenotype enrichment (LVH, high K gradient, volume overload) 🚩 Blinded adjudication 🚩Explicit competing-risk modeling 🚩Patient burden metrics #Nephsky

130

Cristina Popa @nephroseeker.medsky.social · 03/10/2026

7/ Longer/ frequent dialysis reduces UF stress and smooths electrolytes. But hard CV outcomes remain scarce. Trials are often underpowered, single-center, and ignore competing risks like transplant or withdrawal.

111

Cristina Popa @nephroseeker.medsky.social · 03/10/2026

6/ Incremental dialysis may “preserve RRF,” but current evidence is observational, biased, and non‑adjudicated. Healthier patients are selected, not randomized. CV benefit is unproven. Only high‑RRF incident patients with strict monitoring fit the strategy

111

Cristina Popa @nephroseeker.medsky.social · 03/10/2026

5/ Dialysate sodium can be seen as a CV prescription, but current evidence is shaky. Trials are small, underpowered, with non-adjudicated endpoints and inconsistent CMR-LV mass results. ⬇️sodium reduces IDWG/BP yet ⬆️ hypotension. Most studies ignore competing risks+ antihypertensive confounding

110

Cristina Popa @nephroseeker.medsky.social · 03/10/2026

3/ HDx clears larger middle molecules, yet no cardiovascular outcome benefit. Neutral PWV, neutral echo, and rising CAC in HDx. Biology doesn't guarantee outcomes. 🎯Phenotype-enriched, adjudicated trials needed

120

Cristina Popa @nephroseeker.medsky.social · 03/10/2026

2/ High-volume HDF shows the strongest survival signal - but we must stay critical. Prior trials had center effects, adherence bias, and achieved-dose confounding. CONVINCE helps, but the mechanism remains opaque www.nephjc.com/news/convince

120

Cristina Popa @nephroseeker.medsky.social · 03/10/2026

Dialysis adequacy MUST move beyond urea kinetics, and some of us have stated this for years. 🫀The dominant threat is cardiovascular stress: volumes, electrolytes, arrhythmia, LV load, inflammation... Kt/V is not enough #Nephsky academic.oup.com/ndt/advance-...

163

Reposted by Cristina Popa

kireports.bsky.social @kireports.bsky.social · 17/09/2026

1/ HELLP syndrome is usually lumped with #preeclampsia as “the same disease”. This nationwide French study (CONCEPTION) shows that isolated PE (iPE) & PE-HELLP actually diverge in risk factors AND outcomes Why does it matter?

132

Cristina Popa @nephroseeker.medsky.social · 17/09/2026

Preeclampsia and PE-HELLP are often grouped as the same disease, but are they? New nationwide French data from CONCEPTION show distinct risk factors and outcomes, raising a key question: do they carry the same long-term cardiovascular and kidney risk? #Nephsky

031

Reposted by Cristina Popa

kireports.bsky.social @kireports.bsky.social · 09/09/2026

1/ 🚨Tweetorial Alert🚨 Hey #NephSky! Welcome to a 🆕 #skeetorial brought to you by @KIReports @ISNkidneycare. Please also check out www.kireportscommunity.org educational #blogposts. FOLLOW US!

155

Reposted by Cristina Popa

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 15/09/2026

It’s official - EASiKidney - one of the largest kidney trials at ~ 15000 is terminated early www.boehringer-ingelheim.com/human-health... A setback for ASI in CKD (they are going strong in hypertension of course)

boehringer-ingelheim.com

4105

Reposted by Cristina Popa

Nephrology Journal Club @nephjc.bsky.social · 14/09/2026

⏳ Just a bit over one month until #KidneyWk And yes... the legendary #NephJC party is happening again 🎉 🩵Join us, meet the crew, and meet people from across the world 👇Grab your ticket and come be part of the magic www.nephjc.com/news/2026/9/...

nephjc.com

2026 NephJC Night in Denver — NephJC

On FRIDAY night, October 23rd, NephJC will host another legendary NephJC Night during ASN Kidney Week

042

Cristina Popa @nephroseeker.medsky.social · 10/09/2026

#NephJC helped me find my voice and my people- a global community I'm proud to be part of. We can only continue this work with your support 🩵 Donate to keep the magic going 🪄✨

021

Cristina Popa @nephroseeker.medsky.social · 10/09/2026

#NephJC helped me find my voice and my people- a global community I'm proud to be part of. We can only continue this work with your support 🩵 Donate to keep the magic going 🪄✨ #Nephsky

020

Cristina Popa @nephroseeker.medsky.social · 28/08/2026

After three decades without a CKD-pregnancy trial, ORCHARD-BEET is changing that- a multicenter beetroot juice intervention (nitric oxide), with strong feasibility and early signals of kidney and neonatal benefit #NephJC

061

Reposted by Cristina Popa

Nephrology Journal Club @nephjc.bsky.social · 21/08/2026

When our patients start HD, everything gets filtered, except the debate on beta-blocker dialyzability Read #NephJC short about the new target emulation trial, suggesting the non-dialyzables may be doing some heavy MACE-lifting ✍️By @drpallaviprasad.bsky.social nephjc.com/news/targetr...

nephjc.com

Is this the end of the beta-blocker debate in hemodialysis? — NephJC

This week, we will discuss

033

Reposted by Cristina Popa

ASN Publications @asnpublications.bsky.social · 05/08/2026

Is it time for clinicians to rethink “fistula first” for every older dialysis patient? The best access may be the one that aligns with the patient’s health, priorities, and quality of life, according to new research published in #ASNJASN. kidney.pub/JASN1160?... @hswapnil.bsky.social

022

Reposted by Cristina Popa

kireports.bsky.social @kireports.bsky.social · 04/08/2026

10-year Trends in #HeartFailure among Patients with #Dialysis and Non-dialysis #CKD #VisualAbstract by Husam Alzayer www.kireports.org/article/S2468-024…

011

Reposted by Cristina Popa

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 31/07/2026

Guidance on nutrition supplementation in dialysis www.kireports.org/article/S246... In @kireports.bsky.social Increasing protein intake once dialysis begins is important!

1119

Reposted by Cristina Popa

Nephrology Journal Club @nephjc.bsky.social · 31/07/2026

Summer's almost over 😎 #NephSky We know you've been waiting 🏖️ #NephJC Summer Book Club, 9/15/26 discussion! Salama Kassab was a pharmacy student in Syria. Now she helps the wounded who flood through the doors. Set amid the Syrian Revolution, a story of hope, love & possibility.

066

Reposted by Cristina Popa

Nephrology Journal Club @nephjc.bsky.social · 21/07/2026

Want more?? #NephSky #NephJC 🩳FIND-CKD shorts from @CristinaDeReins Finerenone in glomerulonephritis & a pooled analysis of safety and efficacy in CKD (INFINITY) www.nephjc.com/news/2026/7/20/finerenone-shorts

nephjc.com

Finerenone across the proteinuric CKD spectrum — NephJC

Cristina Popa dissects the FIND-CKD extras: GN subgroup and INFINITY analysis

077

Reposted by Cristina Popa

Nephrology Journal Club @nephjc.bsky.social · 12/07/2026

#NephJC Shorts is our new way to share quick takes on notable studies we can’t cover fully 👇👇Check the updated blog page for upcoming Shorts and those already published ✨Suggestions and feedback welcome www.nephjc.com/nephjc-shorts

nephjc.com

NephJC Shorts — NephJC

055

Reposted by Cristina Popa

Nephrology Journal Club @nephjc.bsky.social · 08/07/2026

#NephJC #TenPostNephJC. #NephSky 1/10 Patients with CKD have ⬆️ CVD & bleeding risks but are often excluded from antithrombotic trials, creating a 🔑 evidence gap. Can low dose rivaroxaban safely improve CV outcomes? pubmed.ncbi.nlm.nih.gov/42240165/

143

Reposted by Cristina Popa

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 05/07/2026

A #NephJC short of the telitacicept trial from @nephromommy-akshu.bsky.social www.nephjc.com/news/2026/sh... IMO the exciting part of the early signal of GFR stabilization - if this is recapitulated with atacicept and sibeprelimab - then we can truly say IgAN remission is here and achievable

nephjc.com

NephJC Short: When BAFF Meets APRIL: Telitacicept in IgA Nephropathy (TELIGAN trial) — NephJC

Does Dual BAFF/APRIL Blockade with Telitacicept Reduce Proteinuria in Persistent Proteinuric IgA Nephropathy?

152

Reposted by Cristina Popa

Nephrology Journal Club @nephjc.bsky.social · 05/07/2026

Meeting number 2 is in the books. 🧑‍🏫We reviewed how to blog, create a VA, create a post thread and promote on Insta. So many ways to learn and teach #NephJC #NephSky @dramiliflores.bsky.social @drpallaviprasad.bsky.social @nephroseeker.medsky.social @hswapnil.medsky.social @brianrifkin.bsky.social

043

Reposted by Cristina Popa

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 03/07/2026

The second issue of the journal is live! @theisn.org @arvindcanchi.bsky.social Thanks to the authors, and our reviewers! Everything open access to read: www.kicasereports.org/issue/S3117-... #KICR

0123

Reposted by Cristina Popa

Nephrology Journal Club @nephjc.bsky.social · 02/07/2026

🧂New @freelyfiltered.bsky.social episode on hyponatremia correction #NephJC 🍾How can Brussels champagne help with hypoNa? 🎙️ Special invites: Ewot Hoorn @bettercallseeth.bsky.social 🎙️Filtrate: @kidneyboy.bsky.social @hswapnil.medsky.social @nephcrit.bsky.social www.nephjc.com/freelyfilter...

nephjc.com

FF93 Hyponatremia Interventional Trial — NephJC

Time to fix the sodium! The Hyponatremia Intervention Trial

184

Reposted by Cristina Popa

Nephrology Journal Club @nephjc.bsky.social · 28/06/2026

🦵Had our Kick-off meeting today to welcome a new class of #NephJC interns (year 12 and counting). 👁️Keep an eye out for new blog and VA creators. See if you can Catch'em All🎣 #NephSky #MedSky @hswapnil.medsky.social @kidneyboy.bsky.social @nephroseeker.medsky.social @dramiliflores.bsky.social

088

Cristina Popa @nephroseeker.medsky.social · 26/06/2026

💡Nephrology inpatient volume increased 44%, outpacing other specialties ⏮️ Retrospective, 62 million admissions over 10 yrs 📍Patients became more complex: ⬆️multidisciplinary care, frailty& poorer primary care access 📍Complexity increased mainly independent of aging www.ajkd.org/article/S027...

031

Reposted by Cristina Popa

Nephrology Journal Club @nephjc.bsky.social · 24/06/2026

#NephJC Consensus From GEMRITUX, MENTOR, STARMEN, RI-CYCLO & MAJESTY- the signal remains consistent: ✅ Anti-CD20 therapy works ✅ Remissions are durable ✅ Relapses are lower than CNIs Check out anti-CD20 trials in pMN by @nephroseeker.medsky.social 👇 #NephJC #TenPostNephJC #NephTwitter #NephSky

182

Reposted by Cristina Popa

Nephrology Journal Club @nephjc.bsky.social · 24/06/2026

2/10 What'd I miss? 👀 📍Obinutuzumab: type II anti-CD20 monoclonal antibody, depletes B cells 📍Tacrolimus: ⬇️ T lymphocytes through FK50-binding protein 📍MAJESTY asks: 👑 Can OBI outperform TAC in durable remission while preserving kidney function? #ChatGPT #NephJC #TenPostNephJC #NephSky

161

Reposted by Cristina Popa

Nephrology Journal Club @nephjc.bsky.social · 24/06/2026

1/10 With the incredible wave of glomerular disease and trials showcased at #ERA26, it's time for membranous nephropathy to take the stage Could deeper B-cell depletion finally claim the throne? 👑 Read the article 👇 pubmed.ncbi.nlm.nih.gov/42246654/ #NephJC #TenPostNephJC #NephSky

163

Reposted by Cristina Popa

Nephrology Journal Club @nephjc.bsky.social · 22/06/2026

Is it time for a new leader in membranous nephropathy, or is it just a game of thrones 👑? This week we're discussing OBI vs TAC in the MAJESTRY trial from #ERA26 🏰🐑 #NephSky We welcome back from retirement @jamiekwillows.bsky.social with the summary ✍️ www.nephjc.com/news/2026/06/22-majestyobi

nephjc.com

Heir to the Throne? Obinutuzumab in the membranous nephropathy MAJESTY trial — NephJC

This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy

01210

Reposted by Cristina Popa

Brendon Neuen @brendonneuen.bsky.social · 18/06/2026

PowerPoint slides for the FIND-CKD primary presentation and NOW freely available – including the glomerular disease, data and INFINITY (IPD meta-analysis). Use them, adapt them, share them as you like - All FIND-CKD program presentations and publications now live at www.find-CKD.com

0102